User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide

Primary tabs

download
  • Open access
  • PDF
  • 286.21 K
Bengtsson, D. Schrøder, H. D. Berinder, K. Maiter, Dominique [UCL] Hoybye, C. Burman, P.

(eng) Temozolomide (TMZ) has recently been recommended as the first line chemotherapy in patients with aggressive pituitary tumors (APT) and pituitary carcinomas (PC) not controlled by standard treatment, i.e., surgery, radiotherapy and/or medical therapy (dopamine agonists, somatostatin analogs) [1]. About 40% of patients respond initially to TMZ, complete tumor regression is observed in <10% of patients [2, 3]. The predictive value of the DNA repair protein O6 -methylguanine-DNA methyltransferase (MGMT) as a biomarker for response to TMZ has been debated. Here we present survival data after TMZ treatment in relation to tumoral MGMT content. […]

Document type Article de périodique (Journal article) – Lettre à l'éditeur
Access type Accès libre
Publication date 2018
Language Anglais
Journal information "Endocrine" - Vol. 62, no. 3, p. 737-739 (2018)
Peer reviewed yes
Publisher Humana Press ((United States) Totowa, NJ)
issn 1355-008X
e-issn 1559-0100
Publication status Publié
Affiliations UCL - (SLuc) Service d'endocrinologie et de nutrition
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition
Links
  1. Raverot Gerald, Burman Pia, McCormack Ann, Heaney Anthony, Petersenn Stephan, Popovic Vera, Trouillas Jacqueline, Dekkers Olaf M, _ _, European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas, 10.1530/eje-17-0796
  2. McCormack Ann, Dekkers Olaf M, Petersenn Stephan, Popovic Vera, Trouillas Jacqueline, Raverot Gerald, Burman Pia, _ _, _ _, Hubalewska-Dydejezky Alicia, Assie Guillaume, Bach Leon, Batisse-Lignier Marie, Berinder Katarina, Bilbao Ismene, Bonnet Fabrice, Bresson Damien, Bruno Oscar, Campdera Mariana, Caron Philippe, Castinetti Frederic, Ceccato Filippo, Chabre Olivier, Chanson Philippe, Christ Emanuel, Cloix Lucie, Cortet Christine, Criniere Lise, Cuatrecasas Guillem, Debono Miguel, Delemer Brigitte, Desailloud Rachel, Deutschbein Timo, Dusek Tina, Engström Britt Eden, Faustini-Fustini Marco, Franck Schillo, Garcia Cyril, Greenman Yona, Gil Susana Mallea, Mantovani Giovanna, Gurnell Mark, Heaney Anthony, Henley David, Higham Claire, Hoving EW, Höybye Charlotte, Ichihara Atsuhiro, Jaffrain-Rea Marie-Lise, Johannsson Gudmundur, Jorgensen Jens Otto Lunde, Jublanc Christel, Komor Jan, Korbonits Marta, Kralievic Ivana, Larrieu-Ciron Delphine, Lasolle Helene, Laws Edward, Losa Marco, Maiter Dominique, Marcocci Claudio, Marques Olinda Castro, Mazzuco Tania Longo, Micko Alexander, Bourcigaux Nathalie, Neggers Sebastian, Newell-Price John, Perez-Berida Belén, Ortiz Leon D, Ragnarsson Oskar, Ragonese Marta, Reincke Martin, Sadoul Jean-Louis, Shimatsu Akira, Syro Luis V, Taillandier Luc, Toth Miklos, Usui Takeshi, Valkusz Zauzsanna, Vila Greisa, Whitelaw Ben, Zatelli Maria Chiara, Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016, 10.1530/eje-17-0933
  3. Trouillas Jacqueline, Burman Pia, McCormack Ann, Petersenn Stephan, Popovic Vera, Dekkers Olaf, Raverot Gerald, Aggressive pituitary tumours and carcinomas: two sides of the same coin?, 10.1530/eje-18-0250
  4. Syro Luis V., Rotondo Fabio, Camargo Mauricio, Ortiz Leon D., Serna Carlos A., Kovacs Kalman, Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions, 10.3389/fendo.2018.00318
  5. Campana Davide, Walter Thomas, Pusceddu Sara, Gelsomino Fabio, Graillot Emmanuelle, Prinzi Natalie, Spallanzani Andrea, Fiorentino Michelangelo, Barritault Marc, Dall’Olio Filippo, Brighi Nicole, Biasco Guido, Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study, 10.1007/s12020-017-1474-3
  6. Hegi Monika E., Diserens Annie-Claire, Gorlia Thierry, Hamou Marie-France, de Tribolet Nicolas, Weller Michael, Kros Johan M., Hainfellner Johannes A., Mason Warren, Mariani Luigi, Bromberg Jacoline E.C., Hau Peter, Mirimanoff René O., Cairncross J. Gregory, Janzer Robert C., Stupp Roger, MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma, 10.1056/nejmoa043331
  7. Owen Dwight H., Alexander Andrew J., Konda Bhavana, Wei Lai, Hemminger Jessica A., Schmidt Carl R., Abdel-Misih Sherif R.Z., Dillhoff Mary E., Sipos Jennifer A., Kirschner Lawrence S., Shah Manisha H., Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response, 10.18632/oncotarget.22001
  8. McCormack Ann I., Wass John A. H., Grossman Ashley B., Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status : AGGRESSIVE PITUITARY TUMOURS, 10.1111/j.1365-2362.2011.02520.x
  9. Bengtsson Daniel, Schrøder Henrik Daa, Andersen Marianne, Maiter Dominique, Berinder Katarina, Feldt Rasmussen Ulla, Rasmussen Åse Krogh, Johannsson Gudmundur, Hoybye Charlotte, van der Lely Aart Jan, Petersson Maria, Ragnarsson Oskar, Burman Pia, Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide, 10.1210/jc.2014-4350
  10. Campderá Mariana, Palacios Nuria, Aller Javier, Magallón Rosa, Martín Paloma, Saucedo Gertrudis, Lilienfeld Howard, Estrada Javier, Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment, 10.1007/s11102-015-0694-x
  11. Lasolle Hélène, Cortet Christine, Castinetti Fréderic, Cloix Lucie, Caron Philippe, Delemer Brigitte, Desailloud Rachel, Jublanc Christel, Lebrun-Frenay Christine, Sadoul Jean-Louis, Taillandier Luc, Batisse-Lignier Marie, Bonnet Fabrice, Bourcigaux Nathalie, Bresson Damien, Chabre Olivier, Chanson Philippe, Garcia Cyril, Haissaguerre Magalie, Reznik Yves, Borot Sophie, Villa Chiara, Vasiljevic Alexandre, Gaillard Stephan, Jouanneau Emmanuel, Assié Guillaume, Raverot Gérald, Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas, 10.1530/eje-16-0979
  12. Murakami Mineko, Mizutani Akiko, Asano Shuichiro, Katakami Hideki, Ozawa Yoshinori, Yamazaki Kazuto, Ishida Yasuo, Takano Koji, Okinaga Hiroko, Matsuno Akira, A Mechanism of Acquiring Temozolomide Resistance During Transformation of Atypical Prolactinoma Into Prolactin-Producing Pituitary Carcinoma: Case Report, 10.1227/neu.0b013e318217161a
  13. Giglia-Mari G., Zotter A., Vermeulen W., DNA Damage Response, 10.1101/cshperspect.a000745
Bibliographic reference Bengtsson, D. ; Schrøder, H. D. ; Berinder, K. ; Maiter, Dominique ; Hoybye, C. ; et. al. Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide. In: Endocrine, Vol. 62, no. 3, p. 737-739 (2018)
Permanent URL http://hdl.handle.net/2078.1/215694